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Since the dawn of time, people have pondered which came first: the
chicken or the egg. In biotechnology business planning, the analogous debate
might focus on which must come first strategically: patents and proprietary
rights issues or regulatory strategy for FDA approval. At least insofar as any
attempt to analyze the problem quickly becomes hopelessly circular, the
analogy to the chicken and egg holds up. Of course, without a strong patent
position and proprietary rights to the technology being developed, no
significant investment in the project can be justified. On the other hand,
without a clear and plausible regulatory strategy to FDA approval for a
significant market, no significant investment in the project can be justified.
Furthermore, a company's patent strategy must accommodate its regulatory
strategy. It is important to protect, if at all possible, the use of your
technology in particular indications for which approval might be sought.1
Thus, both patent strategy and FDA strategy are essential, and must fit
* Professor of Law, California Western School of Law and Director, Biotechnology
Programs, at the Center for Molecular Genetics, University of California at San Diego. Professor
Bohrer received his B.A. from Haverford College, a J.D. from the University of Illinois, and an
LL.M. from Harvard Law School. Professor Bohrer has been a member of the faculty at
California Western School of Law since 1982 and has chaired or co-chaired the Annual
California Biotechnology Conference since its inception in February of 1985.
1. For example, Acme Biotech may have filed an application for a newly discovered growth
factor, which covers the composition of matter itself. Sometime later, it is discovered that this
particular growth factor is essential for the differentiation and maturation of dopaminergic
neurons, a cell-type that is central to and deficient in persons with Parkinson's disease, making
Parkinson's an attractive first target (in FDA parlance, "indication") for the company's research
and development plan. It is not only possible, but essential to file an additional patent
application claiming a method for treating Parkinson's disease with the growth factor. This not
only prevents anyone else from making the same discovery independently and potentially gaining
patent rights in the U.S. or elsewhere that would block Acme from using its own compound for
that indication, but also would start a new twenty-year patent term from the date of the second
application, thereby extending the Acme's period of patent protection, at least for that new
indication.
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together. The intrinsic importance of patent and FDA issues to the biotech-
nology industry provided the impetus for the Twelfth Annual California
Biotechnology Conference, which brought together an international panel of
experts to discuss their views of recent developments in those crucial areas.
That is why I am especially pleased to provide a foreword to this symposium
focused on two cornerstones of today's biotechnology industry, patents and
the new drug approval process of the FDA, and to provide some of my own
"lawyer's view" of strategic planning for biotechnology.
Section I of this Article is a brief analysis of the market issues in the
biotech business plan. Section II extends the analysis of market issues in
relationship to regulatory strategy. Section III provides a synopsis of the
financing issues that are involved in planning for a new biopharmaceutical in
the context of a small dedicated biotechnology company,2 as well as the
interplay between financial strategy and other strategic issues. Section IV
completes the overview of the process of developing biopharmaceuticals, with
particular emphasis on the issues raised by the contributors to this sympo-
sium.
I. DEFINING AND CHOOSING A MARKET:
THE ROLE OF THE FDA AND REGULATORY STRATEGY
Most business plans, whether for a cookie franchise or an Internet
software venture, begin with an effort to predict the potential market for the
potential product. For many products, this can be very difficult to ascertain.
For most biotechnology-based health care products, the task of determining
the size of the potential market is actually somewhat easier than predicting
how many people will buy a new flavor of ice cream. This is because the
market for most biotechnology products is determined by the disease or
health-related condition for which the product might be used. In most cases,
reasonable data as to the number of patients per year with a particular disease
is readily available, whether for the U.S. market, the European Union member
states, or Japan. In the United States, the Center for Disease Control is a
major source of such epidemiological data. There are also patient advocacy
groups that have fairly accurate data on the numbers of patients suffering
2. "Dedicated biotechnology company," or "DBC," is a term used to refer to small and
emerging companies that have been founded with the exclusive intention of developing and
applying biotechnology to produce a new product or products. Since biotechnology's techniques
are now used throughout the pharmaceutical industry, as well as other industries such as
agriculture, the term DBC is particularly useful in distinguishing small, exclusively biotech-
nology-focused companies from larger, well-established companies such as large pharmaceutical
companies, that have now begun to incorporate biotechnology into their research and
development. Business planning for a DBC involved in developing a new biopharmaceutical is,
necessarily, significantly different than it is for a large pharmaceutical company such as Merck
or Pfizer. Such large companies are easily able to finance development of new products from
existing revenues, whereas DBCs generally are financed piecemeal, over time, with the status of
the next planned funding always dependent on the success of the prior stage of development.
It is impossible to overstate the significance of these funding constraints for the DBCs,
particularly for strategic planning.
[Vol. 33
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from a wide range of diseases. However, the role of the potential market
variable in strategic planning for a new biotech product differs from market
considerations for a consumer product in two very important ways.
The first difference is that the market for a biopharmaceutical or
diagnostic is more or less legally restricted to the precise use indicated on its
product label' for which the FDA approved its marketing. Thus, a drug's
label might state, for example, that it is indicated for use in the treatment of
relapsing/remitting multiple sclerosis; or, alternatively, it might state that it
is for use in the treatment of all forms of relapsing multiple sclerosis (a more
broadly inclusive patient population than the former indication). Whereas a
cookie baker may try to entice absolutely anyone to buy his wares, whether
to eat as a snack or to break up and to use in a pie crust, a manufacturer of
a new drug may not promote the use of its product for any indication which
the FDA has not approved for its labeling.4 Thus, even though it is perfectly
proper (and commonly done) for a physician to prescribe a drug for a
condition for which it has not been approved, in most cases the market for
a drug will be restricted to some share of the patient population with the
indication for which FDA approval is obtained.6
I. REGULATORY STRATEGY
(MARKETS AND PLANNING FOR THE FDA)
The second major difference between market analysis for a biotech
strategic plan and that for other types of goods is that, unlike a business plan
for most consumer products, which would assume that the bigger the potential
market the better, making a similar assumption for a biopharmaceutical is
often a mistake. The reason is that for biopharmaceuticals, different markets
can require substantially different development costs, both in development
time and in actual dollars expended on direct development costs. Most
3. Actually, "package insert" is more literally correct.
4. This particular position of the FDA is quite clearly set forth in the Draft Policy Statement
on Industry-Supported Scientific & Educational Activities, 57 Fed. Reg. 56,412 (1992). It is
reiterated by the FDA in Citizen Petition Regarding the Food & Drug Administration's Policy
on Promotion of Unapproved Uses of Approved Drugs & Devices; Request for Comments, 59
Fed. Reg. 59, 820 (1994), which also reveals some of the important dimensions of the
controversy surrounding this stance by the FDA. It has not, however, been statutorily codified,
nor has it been the subject of a notice-and-comment rule-making by the FDA. See Boulding, The
Statutory Basis for FDA Regulation, 4 J. PHARMACY & L. 123 (1995).
5. For example, prescribing human growth hormone for an extremely short child who is not
suffering from a hypopituitary shortage of endogenous growth hormone, so that in some cases
the market for a drug may in fact significantly exceed the total patient population for which it
has been approved.
6. The ultimate share of the patient population that a drug will achieve will, obviously
depend on its advantages over other therapeutics and its price, as well as other factors. However,
for a breakthrough drug, that is one that offers significant efficacy for a serious disease which
currently has no effective therapy, which is the goal that drives most biotechnology companies,
the likely actual market for the drug may optimistically, yet reasonably, be conceived of as 60%
or more of the patient population a few years after product launch.
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biotechnology companies are in the research and development phase,
spending significant amounts of money without yet having a product on the
market, let alone earning a profit. Therefore, it may well make more sense
to embark on a four-year, $25 million effort to win approval to enter a $100
million market, than to work on a six-to-eight-year, $120 million effort to
enter a $500 million market.
These kinds of time and money differences can exist even when the same
compound could be developed for multiple indications. For example, a
company might have developed a compound which seems to have potential
for protecting neurons from the damage which occurs in such differing
neurodegenerative diseases as Parkinson's disease and Alzheimer's disease.
An example is a neurotrophin, such as GDNF.7 Of the two diseases,
Alzheimer's is by far the larger market. Nevertheless, Parkinson's may well
be the preferable clinical target because a variety of clinical considerations
make Alzheimer's a much more difficult and expensive target, even if the
compound ultimately works.
Alzheimer's is a very slowly progressing disease, with a highly variable
course that can take from one to five years or more from diagnosis to a
nearly complete loss of cognitive function.' Trials must therefore follow
patients closely for a very long period of time, probably eighteen months to
two years, 9 in an attempt to measure significant differences between the
patients' rate of loss of function in the treatment group versus the control
group.1" Additionally, the extreme variability in the rate of progression
7. See e.g., Moore, Klein, Farinas, Sauer, et al.; Renal and NeuronalAbnormalities in Mice
Lacking GDNF, NATURE, July 4, at 76-9, abstract available in LEXIS, Medline library
(suggesting that glial-derived neurotrophic factor (GDNF) could be "considered a potential
therapeutic agent for Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's
disease").
8. See e.g. Kraemer, Tindenberg, Yesavage, "How Far" vs. "How Fast" in Alzheimer's
Disease, 51 ARCH. NEUROLOGY. 275-9 (Mar. 1994), abstract available in LEXIS, Medline
library.
9. Morris, Edland, et al., The Consortium to Establish a Registry for Alzheimer's Disease
(CERAD), Part IV Rates of Cognitive Change in the Longitudinal Assessment of Probable
Alzheimer's Disease, 43 NEUROLOGY 2457-65 (Dec. 1993)(". . . there is need for an accurate
analysis of large numbers of persons with the disorder studied over long periods .... We found
that rate-of-change determinations are less reliable when the observation period is 1 year or less,
that dementia progression may be nonlinear when described by certain measures, and that simple
change scores do not accurately characterize the rate of decline.") (quotation from abstrasct
available in LEXIS, Medline library).
10. A difference in the rate of disease progression, rather than a measure of improvement
over time, would be the goal in any Alzheimer's disease trial that is now foreseeable for such
neurotrophins as GDNF. Alzheimer's disease is produced by the death of neurons involved in
cognitive functions. Once dead, the neurons and their functions cannot be restored with any
technology that is now within the realm of contemplation. At best, a treatment would completely
arrest the progression by preventing any more neurons from dying, or, more likely, slow the rate
of further neuronal death. This having been said, however, the only currently approved drug for
Alzheimer's (trade name Cognex, composition name tacrine) is designed to improve function
over placebo on tests of cognitive functioning, primarily by getting a bit more action from the
remaining neurons while the drug is active, in much the same way that a non-Alzheimer's patient
may do better on some short-term memory tests after a small dose of caffeine or other stimulant.
In our hypothetical, GDNF would not be likely to act via short-term stimulation, but rather by
[Vol. 33
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among patients makes larger groups necessary to provide statistical signifi-
cance to the differences between groups in order to overcome the random
"noise" of the underlying variations which can mask the treatment's effect in
smaller groups."
Parkinson's disease, on the other hand, progresses differently. Though
the disease itself is caused by a progressive loss of dopamine-producing
neurons of the substantia nigra region of the brain, at least in the earlier
stages of the disease, the loss of function is reversible if the dopamine levels
in the affected areas of the brain are raised. Thus, a treatment for Park-
inson's that results in sufficient endogenous dopamine production either from
a new source 2 or from protection and stimulation of the remaining do-
paminergic neurons of the substantia nigra could result in the improvement
of Parkinson's patients, rather than a mere slowing of the disease's progres-
sion. As a result, one would expect that an effective Parkinson's therapeutic
would make its effect clear in a smaller group of patients and over a shorter
period of time. 3
For example, assume that the time from initial animal tests to FDA
approval for an Alzheimer's indication will be eight years, with clinical trials
on two thousand patients for Phases II and I combined, and a per patient
cost of $12,000.00.' This Alzheimer's market entry will carry with it direct
clinical trial costs of $24 million. We might also estimate that the time to
FDA approval for a Parkinson's indication will be six years, with a total of
1000 patients for Phases II and 111 combined, and a cost of $6000 per patient
or $6 million in direct clinical costs. For most biotech companies, the shorter
and cheaper route to an approved Parkinson's indication makes much more
sense; this is true even if the ultimate annual sales never exceed $300 million
rather than the approximate $1.5 billion an effective Alzheimer's drug might
command. After all, the profits on the first indication (and the money that
can be raised as its likelihood of success increases) can easily fund the longer,
more expensive effort to enter the larger market. The choice of the initial
actually (potentially significantly) slowing the rate of neuronal death over a long period of time,
requiring a clinical trial to show differences in rates of change over time, rather than short-term
improvements in cognition over placebo.
11. See supra note 5.
12. For example, the sometimes successful efforts to transplant fetal neurons into the brains
of Parkinson's disease patients.
13. A cinematic depiction of the dramatic effect (although it is unfortunately short-lived)
of medication on advanced Parkinson's disease is the film Awakenings based on the book of the
same name by neurologist Oliver Sachs.
14. This discussion assumes that which is generally true, i.e. that longer clinical trials not
only are more expensive by virtue of the continuing indirect costs (rent, depreciation, patent life
amortization, general payroll, etc.) that are consumed during the trial, but also in direct costs.
This is generally true because the longer trials typically require a proportionately greater number
of patient observations, laboratory analyses, and physician examinations. If, for example, the
protocol requires blood to be drawn from each patient every month for complete analysis, a two-
year trial requires 18 more such tests than a six-month trial. The same logic affects each of the
major components of direct clinical costs. Additionally, the more data, the more difficult and
expensive the process of data analysis and FDA filing.
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target then helps define not only the product development pathway, but goes
a long way towards defining the financing pathway.
III. FINANCING BIOPHARMACEUTICAL DEVELOPMENT:
CONSIDERATIONS AND STRATEGY
The development pathway and initial target provide the three key
parameters that drive financing: (1) the anticipated development costs, (2) the
anticipated revenues, and (3) the timing of developmental milestones. The
first two, anticipated revenues and market share, together with the estimated
per unit price and rough cost, give an annual figure for gross profits that is
the key variable in determining the rate of return on varying levels of prior
investment. Thus, the business plan should demonstrate to the venture
capitalist providing early funding and the investment bankers providing later-
stage financing, that the well-thought-out first indication will translate into an
adequate return on the investments required to pay the development costs.
For the third variable, the timing of development milestones, the criteria
for initial public offerings or major corporate partnerships change over time
(from early phase development on the one extreme to positive Phase II data
with Phase II commenced on the other extreme). Even so, the milestones
that are penciled in for the first indication can be prospectively equated with
financing benchmarks. A plan that involves commencing Phase II trials
within 24 months allows the inference that a major venture round or
financing commitment from a corporate partner could be closed prior to
Phase II trials if no adverse results are produced in Phase I or a Phase M1II.
Similarly, positive Phase II data should certainly be enough to bring a strong
possibility of an IPO.
The corollary of all this is, of course, that given the estimated expense
of development as it is projected forward in time, each preceding investment
or investments must be sufficient to carry the company to the next develop-
ment phase and its accompanying opportunity for new money. Thus, the
lawyer who is assisting in the negotiation of a venture capital financing or a
corporate partnering/licensing agreement for a biotechnology company will
not only need to understand the milestones provided for in the particular
agreement, but must also understand that round of financing's place in the
overall structure of product development. Although plans are inevitably
subject to change due to a variety of unpredictable circumstances, manage-
ment, with the assistance of legal counsel, needs to develop and revise on an
ongoing basis an overall plan for financing the company through to
profitability. An example of such a plan as it might look at the very
beginning of development appears in Figure 1.
One of the greatest challenges for the emerging biotechnology company
and its legal counsel is to integrate its intellectual property and regulatory
strategies with its financial plan. This effort at long-range planning is
complicated by two keys facts. First, the actual marketability to pharmaceu-
tical company partners of particular development milestones (such as
[Vol. 33
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completing a Phase I study) will vary with the cycles of the pharmaceutical
companies' need for products and the general stock market conditions for
biotechnology. Second, however, the marketability will also need constant
and sometimes major adjustments as product development provides new
opportunities and disappointments.
For example, let us assume that CURALL Biotech, the company depicted
in Figure 1, is developing a technology based on monoclonal antibodies. The
competitive advantage of this technology is that it targets a proprietary
antigen (antibody target) which is a variant cytokine (inter-cellular messenger,
usually a growth factor) receptor found on the surface of cancer cells, but not
normal cells. The antibody binding to the target prevents the regular
messenger from binding to the receptor. It also stimulates the immune
system's response to the target cells (a regular function of antibodies) because
deprivation of the cytokine signal shuts down the cell's proliferative pathway
and slows the growth of the cancer cells by an additional route.
Based upon this brief synopsis of the technology, proprietary rights might
be sought for the purified and isolated receptor protein, assuming that the
variant found on cancer cells was not previously known. Propriety rights
would also be sought for the gene sequence encoding the variant receptor,
methods of making the receptor protein, the use of the receptor as a screen
for small molecules that might be effective anti-cancer agents, antibodies
targeting the receptor and their use in cancer therapy, and particular
antibodies that have been identified as particularly useful because of their
affinity and specificity.
The strategic issues of relating these proprietary rights to regulatory
strategy and financing goals can be appreciated after a brief look at the initial
technology and its possible development paths. Assume that the first
antibodies are chimeric antibodies. These antibodies are made by combining
the genes for the antigen-binding (variable) regions of an original mouse
antibody to the receptor with the genes for the constant regions of a human
Ig G antibody in Chinese Hamster ovary cells. This then produces the
mouse-human chimeric antibody. Possible results of CURALL's research and
development may include a second-generation antibody that is fully human
in its genes for both variable and constant regions.
7
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FIGURE 1A
The initial business plan for financing a new biotechnology company
(CURALL Biotech) to develop proprietary therapeutics for treating cancer.
Initial Product Target (CA122): Dukes' B colon cancer, adjuvant to surgery
and standard chemotherapy.
Second Product Target (CA945): Advanced Ovarian Cancer (with second
indication breast cancer).




for years 4 and 5
Additional $40 million
(Year 9 product launch
and profit)
Milestones
Identification of First Lead
Compound (CA122), initial screen-
ing, preliminary work on identifi-
cation of second lead:
CA122 completion of Phase I/If
and Phase II(a) on CA122
CA945 complete toxicology and
Phase I
CA 122 Complete Phase III and file
NDA ($20 million)
CA945 Complete Phase II and
initiate Phase 111 $10 million
Other Projects at that point: $10
million
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FIGURE lB












End of Year 3
End of Year 4
End of Year 6
Identification of lead compound;
successful completion of animal
model, initial non-GLP toxicology
$4 million venture capital. Mile-
stones: Completion of Phase I/I
Corporate Partnership: European
and North American Rights to first
compound in all cancers. Licensing
Fee, Equity, Milestones. Full Di-
rects Cost of Further Toxicology,
Clinical Trials and Regulatory
Submissions. Cash over costs
(from partner):
$4 million in first two years,
($15 million additional by year 5)
$25 million IPO
$25 million secondary offering.
TOTAL FINANCING ANTICIPATED THROUGH YEAR 8: $77 MILLION
(Hurray!)
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Efforts might also be directed to the development of a cancer "vaccine"
that uses the receptor protein with a vaccine "adjuvant" (or some other
method that stimulates a strong immune response to the variant receptor) and
thus, theoretically, to cancer cells which display the variant receptor protein.
Still other research efforts might be directed to synthesizing or screening for
small molecules that also bind to and inhibit the receptor. Other efforts may
seek to make antibody fragments that bind to the receptor and inhibit the
binding of the cytokine (but do not stimulate immune function), or antibody
fragments that are linked to a toxin such as ricin. Such fragments would
replace the antibody's immune system response potential with a cytotoxic
chemical function.
All of these possibilities are being considered and juggled with some
development opportunities selected for initial exploration. We will also
eventually learn much about the particular cancer targets, the responsiveness
of each cancer type at different stages, and the effect of using the antibody,
its second or third generation alternatives (fully human, small molecules,
antibody fragments, and so on), or the receptor-based vaccine, in conjunction
with traditional therapies and surgery. As the second or third generation
compounds are developed, they will generate additional proprietary rights that
will need to be pursued. If the company is successful in generating sufficient
venture capital to take the first-generation antibody through a relatively
successful Phase I/ll trial, the model in Figure 1 suggests that the time would
be right for a corporate partnership, giving up the rights to the first-generation
antibody in exchange for cash and development funding. It is, however,
likely that the partner will want rights to some of the potential additional
technology that can be developed as well.
It is at the stage of this initial corporate partner negotiation that the
strategic issues of proprietary rights, financing, and regulatory strategy
become urgent. At the same time, these issues reveal their complexity. How
can the (hopefully ever-) increasing bundle of proprietary rights be allocated
between CURALL and its first partner? What can CURALL keep for itself
and what should its own development priority be? What problems might
arise if the line between meum and teum (CURALL and partner) is not sharp
enough to avoid conflicts of interest and ultimately competition? 5 There
are no hard and fast rules that can guide the strategy and the negotiation; but
it is clearly essential to have a good grasp of the technology, its development
costs for different kinds of compounds and different indications (particularly
with respect to obtaining FDA approval), and the scope of available intel-
lectual property protection.
15. For the classic example of litigation arising out of a biotech pie too finely cut, see Ortho
Pharm. Corp. v. Amgen, Inc., 887 F.2d 460 (3d Cir. 1989).
[Vol. 33
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IV. CONCLUSION: CURRENT IssuEs IN THE LIFE
CYCLE OF BIOTECHNOLOGY
This brief look at the lawyer's perspective on biotechnology business
planning underscores the importance of patent predictability, as well as FDA
predictability, in any biotechnology business strategy. The past 18 months
have been exceptionally noteworthy for the biotechnology industry generally
and for developments in biotechnology law. The transition to a world-wide
intellectual property regime within the framework of GATT, the resolution
of the controversy over the utility requirement in biotechnology patent
applications for potential therapeutics, and a major effort at changing or
reforming the FDA's regulatory process were just some of the major
developments that led to the planning for the conference upon which this
symposium is based. The debate between Dr. Edward Penhoet"6 and
Commissioner Bruce Lehman'7 over the GATT-imposed changes in the
duration of patent protection dramatically illustrates the importance of patent
term protection for the biotechnology company. Eileen McMahon's
symposium contribution" underscores the significance of the international
dimensions of these intellectual property issues.
In terms of biopharmaceutical development strategy from the lawyer's
perspective, it is clearly important to get into the marketplace sooner, with a
greater patent term remaining-even to the extent of influencing, if not
dictating, the choice of initial target indication for a biotechnology company's
lead compound.' 9 At the same time, any examination of the issues in
planning for a biotechnology company also reemphasizes not only how
important it is for the FDA to act swiftly, but also how impqrtant it is for the
FDA to provide companies with enough information about the requirements
of prospective clinical trials to enable companies to make appropriate
decisions about alternative development pathways.2"
16. Edward Penhoet, Ph.D., Science & Technology Policy: A CEO's View, 33 CAL. W. L.
REV. 15 (1996) (this volume).
17. See Bruce Lehman, Major Biotechnology Issues for the U.S. Patent and Trademark
Office, 33 CAL. W. L. REV. 49 (1996) (this volume).
18. Eileen MeMahon, NAFTA and the Biotechnology Industry, 33 CAL. W. L. REV. 31
(1996) (this volume).
19. The patent term extension provisions of 35 U.S.C. § 155(A) to § 156 partially mitigate
the effect of the period of time necessary to test and obtain approval for new drugs, as only one-
half of the testing time can be credited and the total credit (one-half testing time and all time
from NDA filing to approval) is capped at a maximum of five years. Thus, every year of
additional time in the clinic can extend a patent term a maximum of six months.
20. It is, of course, always possible that new information or understanding about a disease
will necessitate changes in regulatory requirements for clinical trial data. For example, as
continuing research into AIDS has increased our understanding of the dynamics of the disease,
it is both natural and appropriate that the FDA require that clinical trials measure viral load as
well as CD4 counts. However, absent such significant changes in the basic understanding of a
disease, once the company and an appropriate FDA official have agreed that in a Parkinson's trial
the principal measurement will be clinical measurements of muscle strength, flexibility, and
function, it is simply devastating to have the NDA rejected because the reviewer felt that NMR
11
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The symposium contributions by Dr. John Ashworth2 and Dr. Martine
Kraus22 provide significant insight into the importance of regulatory speed
and consistency. Dr. Ashworth's article looks at the role of regulation in an
extraordinarily informative examination of the range of cultural and political
variables that have contributed to the relative lag in biotechnology develop-
ment in the countries of the European Union (EU). Dr. Kraus's article is
based upon her detailed case studies of how the regulatory process in the EU
and the U.S. affect the availability of pharmaceuticals and the cost of
pharmaceutical development.
While Ashworth and Kraus'provide an illuminating picture of the recent
or current state of regulation and other factors in the EU and U.S., the articles
by Lynne Lawrence 3 and Greg Simon24 are significant contributions to the
debate about the future of FDA regulation in the United States. Particularly
noteworthy is the significant bipartisan effort that Ms. Lawrence describes,
led by Senator Kassebaum for the Republicans and Senator Mikulski for the
Democrats, to bring about significant changes in the FDA's statutory
authority and requirements. It is equally noteworthy to observe the remaining
fundamental differences between the Mikulski-Kassebaum approach to FDA
reform and the Clinton Administration's response, as set forth in Greg
Simon's article.
Since the symposium, Senator Kassebaum has retired, President Clinton
has been reelected, and the 104th Congress has adjourned without addressing
FDA reform. The issue is almost certain to arise in the next Congress how-
ever, and there can be no doubt of its significance for the biotechnology
industry.
Finally, I would be remiss in this lawyer's perspective on biotechnology
if I did not acknowledge that, despite the sound and fury over patents and
FDA approval procedures, the most fundamental role that the federal govern-
ment plays in the development of biotechnology is not at the point of
commercial inception, through a sound system of intellectual property
protection; neither is its most important role played during the long process
of commercialization by laws and policies which promote a healthy
investment climate; nor is it at the point of market entry, through approval by
the FDA, or even after market entry, through the Health Care Financing
Administration's reimbursement of Medicare and Medicaid expenses for
patient's use of biotechnology products. Rather than all of these areas, in
data on neuronal deterioration should have been supplied.
21. John Ashworth, Ph.D., Development of the European Biotechnology Industry, 33 CAL.
W. L. REV. 83 (1996) (this volume).
22. Martine Kraus, Ph.D., A Comparison of Drug Approval at the FDA and the CPMP, 33
CAL. W. L. REV. 101 (1996) (this volume).
23. Lynne Lawrence, Moving Science and Technology Policy Forward: The Role of
Congress, 33 CAL. W. L. REV. 73 (1996) (this volume).
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which law and lawyers play a significant role, the greatest contribution of the
federal govemment to the development of biotechnology is through the
agency that is least staffed by lawyers and least bound up in administrative
procedure: the National Institutes of Health (NIl!).
Federal funding of research in molecular biology, biochemistry, and
molecular genetics, primarily by the NIH, is unquestionably the driving force
behind the growth of the biotechnology industry and United States' preemi-
nence in biotechnology. As Dr. Floyd Bloom's symposium contribution on
U.S. science policy' makes painfully clear, our commitment to basic science
and a continuation of a science policy that supports basic research is of vital
importance.
25. Floyd Bloom, M.D., Science and Technology Policy: A Scientist's View, 33 CAL. W.
L. REV. 63 (1996) (this volume).
13
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